CRISIL upgrades Sahajanand Medical and subsidiary bank facility ratings

Credit rating upgradedCredit & Debt View source PDF Explain this filing

SMT · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.1%Reaction day

₹486.30

prior close

₹489.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.1%-1.0% vs market

On the reaction day the stock moved 1.0 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.1

10m

-1.8

15m

-0.1

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

+0.1+1.1-1.0

Next day

+7.4pendingpending

———

15d

———

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

CRISIL upgraded the company's Rs 300 crore bank facilities to A-/Stable from BBB+/Stable and its short-term rating to A2+ from A2. Subsidiary SMT Cardiovascular's Rs 50 crore facilities were upgraded to BBB+/Stable from BBB/Stable. CRISIL cited 18% FY2026 revenue growth to Rs 1,214 crore, stable profitability and adequate liquidity.

Likely market impact

The upgrade signals lower credit risk and may improve borrowing terms and investor sentiment, supporting the stock, but does not guarantee price gains.